A Rhode Island man became the first patient worldwide to receive Biogen’s hotly debated Alzheimer’s drug outside of a clinical trial on Wednesday, a hospital spokesperson confirmed to Fox News.
Marc Archambault, 70 of Wakefield, received the infusion shortly before noon at Butler Hospital in Providence, according to spokesperson Raina Smith of Care New England. The patient met the criteria for people diagnosed with mild cognitive impairment or early Alzheimer’s disease, Smith said.”It’s transforming how we treat Alzheimer’s,” Dr. Stephen Salloway, director of the memory and aging program at Butler Hospital, said at a press conference. “For those of you who don’t know, it’s a devastating disease.”
“Marc actually tried out for aducanumab [trials] twice but he flunked because he did too well on his memory tests,” Salloway said. “We knew he had Alzheimer’s and he was building up amyloid plaques in the brain and had an increased genetic risk for Alzheimer’s.”
The patient, Archambault, also spoke during the press conference, thanking his doctors.
“It’s just amazing to think that this will be helpful and the other drugs that will come in the future so that my children don’t have to worry about it as well, and my family,” Archambault said.
“It’s a slow situation, I still work, I’m a realtor,” he continued, reflecting on his course of disease. “A few years ago I realized I was gonna have to retire…luckily my real estate brain is still here.”
